Previous Close | 0.9900 |
Open | 1.0100 |
Bid | 1.0000 x 1200 |
Ask | 1.0200 x 1000 |
Day's Range | 0.9903 - 1.0100 |
52 Week Range | 0.8800 - 6.2200 |
Volume | |
Avg. Volume | 552,120 |
Market Cap | 15.989M |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6110 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for AEMD
By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expanding the Potential Indications for Hemopurifier Treatment Aethlon Medical’s (NASDAQ:AEMD) clinical trials are moving forward and expanding, as AEMD continues to demonstrate the effectiveness of its lead product, the Aethlon Hemopurifier®, in a broad range of viruses and conditions in single patient emergency use cases and in in vitro
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical technology company focused on developing products to diagnose and treat life and organ threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2022 and provided an update on recent developments.
Aethlon Medical, Inc. (Nasdaq: AEMD), a company developing medical technology to treat cancer and life-threatening infectious disease, today announced that it will issue financial results for its fiscal year ended March 31, 2022, at 4:15 p.m. EST on Tuesday, June 28, 2022.